Orencia (abatacept) (Rheumatoid Arthritis) Is Expected To Grow To Just Over 8.5 Million Individuals By 2023: Hexa Reports

Get key Market Research Reports and Insightful Company Profiles
Hexa Reports Added “Orencia (abatacept) (Rheumatoid Arthritis)” Research Report to its huge Database.The anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease.

However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Browse Detailed Report With TOC at:

BMS’ Orencia (abatacept) is a soluble biologic, and structurally, is a fully-humanized fusion protein of the extracellular domain of the human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with the Fc domain of human IgG1. The drug functions by preventing T-cell activation. The co-stimulatory molecules CD80 and CD86 are able to bind to CTLA-4, which typically blocks T-cell activation, or to CD28, which activates T cells. Because CTLA-4 has a higher affinity for CD80 and CD86, Orencia is able to block the activation of T cells by competing with CD28 for binding to CD80/CD86.


Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Orencia (Abatacept) including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Orencia (Abatacept) for the top 9 countries from 2013 to 2023.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and India.

Browse Reports On “Pharmaceuticals & Healthcare” at:

Reasons To Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.
Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
Make more informed business decisions from insightful and in-depth analysis of Orencia (Abatacept) performance.
Obtain sales forecast for Orencia (Abatacept) from 2013-2023 in top 9 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia and India).

Request A Sample copy of This Report at:

About Us:

Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Visit Our Website: http://www.hexareports.com

Media Contact
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Email: Send Email
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://www.hexareports.com/report/orencia-abatacept-rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details